M. Laura Martin, Ph.D., leads efforts in the utilization of patient-derived models of cancer, studying the functional impact of genetic and epigenetic alterations in preclinical models, and investigating the potential to translate these findings to clinical relevance. She focuses on the expansion of the ex-vivo model program with particular interest in generating models from non-cancer disease groups, improving the rate of successful model development, and increasing applications for which ex-vivo models are used for research across the campus.
Learn more about our Organoid Platform here.